Get the Stockscreener App
0.9604
3.27%
0.0304
After Hours:
.93
-0.0304
-3.17%
Elutia Inc stock is traded at $0.9604, with a volume of 21,667.
It is up +3.27% in the last 24 hours and down -3.86% over the past month.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
See More
Previous Close:
$0.93
Open:
$0.969
24h Volume:
21,667
Relative Volume:
0.20
Market Cap:
$42.46M
Revenue:
$15.97M
Net Income/Loss:
$-24.40M
P/E Ratio:
-1.2662
EPS:
-0.7585
Net Cash Flow:
$-45.82M
1W Performance:
+3.26%
1M Performance:
-3.86%
6M Performance:
-3.96%
1Y Performance:
-49.98%
1-Day Range:
$0.904
$0.9907
1-Week Range:
$0.90
$1.00
52-Week Range:
$0.50
$2.50
Elutia Inc Stock (ELUT) Company Profile
Name
Elutia Inc
Sector
Industry
Phone
240-247-1143
Address
12510 PROSPERITY DRIVE, SILVER SPRING
Compare ELUT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
0.9604 | 41.11M | 15.97M | -24.40M | -45.82M | -0.7585 |
ABT
Abbott Laboratories
|
104.49 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
336.74 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
84.22 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
45.51 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.04 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-02-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-02-20 | Initiated | Cowen | Outperform |
| Nov-02-20 | Initiated | Piper Sandler | Overweight |
| Nov-02-20 | Initiated | Truist | Buy |
Elutia Inc Stock (ELUT) Latest News
Elutia Inc (ELUT) Cash Flow - TradingKey
Elutia Inc (ELUT) Balance Sheet - TradingKey
Elutia Inc (ELUT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Elutia Inc (ELUT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
ELUT|Elutia Inc|Price:0.930|Chg%:-0.003 - TradingKey
Elutia Inc (ELUT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Elutia, Inc. Revenue Breakdown – NASDAQ:ELUT - TradingView
Elutia, Inc. Revenue Breakdown – BOATS:ELUT - TradingView
Elutia Inc (ELUT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Elutia Inc (ELUT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Elutia Sells SimpliDerm Business for Up to $11M to Fund NXT-41x Launch in $1.5B Plastic Surgery Market 1 - Minichart
Elutia Divests SimpliDerm Assets to Refocus Strategy - TipRanks
Lake Street Reaffirms Their Buy Rating on Elutia (ELUT) - The Globe and Mail
Elutia Sheds Legacy Business to Chase $1.5 Billion Market Opportunity - Benzinga
Elutia Agrees to Sell SimpliDerm for Up to $11 Million - marketscreener.com
Elutia to sell SimpliDerm business for up to $11 million - Investing.com
Elutia (ELUT) Finalizes Sale of SimpliDerm Business for Up to $1 - GuruFocus
Cellution Biologics Inc. Signs Definitive Agreement to Acquire SimpliDerm® Human Hydrated Acellular Dermal Matrix Business from Elutia Inc., Expanding its Allograft Portfolio - The Manila Times
Cellution Biologics Inc. Signs Definitive Agreement to - GlobeNewswire
Elutia Signs Definitive Agreement to Sell SimpliDerm® in - GlobeNewswire
Elutia Inc. (ELUT) Holds Steady Near Support as Uptrend Faces ResistanceGrowth Stock Picks - dars.gov.et
Elutia Inc. (ELUT) Q1 2026 Earnings: EPS Misses Estimates Amid Strategic ProgressProfit Recovery Report - dars.gov.et
Elutia Inc. (ELUT) Bounces From Support, Tests Key Resistance at $1.01RVOL Breakout - dars.gov.et
Elutia (ELUT) Q1 2026 Earnings: EPS Miss Weighs on Sentiment Amid Ongoing RestructuringDividend Cut Risk - DonanımHaber
Elutia Inc.(NasdaqCM: ELUT) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Elutia Inc.(NasdaqCM: ELUT) added to Russell 3000E Growth Benchmark - marketscreener.com
Elutia Inc Class A Actuals & Estimates (NASDAQ:ELUT) - TradingView
Enterprise value to EBITDA forward of Elutia, Inc. – NASDAQ:ELUT - TradingView
Price to sales forward of Elutia, Inc. – NASDAQ:ELUT - TradingView
ELUT Forecast — Price Target — Prediction for 2027 - TradingView
Elutia Holds Near Key $1 Level After Marginal DeclineGolden Cross - dars.gov.et
Enterprise value to revenue forward of Elutia, Inc. – NASDAQ:ELUT - TradingView
Price to book forward of Elutia, Inc. – NASDAQ:ELUT - TradingView
Price to earnings forward of Elutia, Inc. – NASDAQ:ELUT - TradingView
Enterprise value to EBIT forward of Elutia, Inc. – NASDAQ:ELUT - TradingView
Form 4 Elutia Inc For: 22 June By Investing.com - Investing.com South Africa
Elutia (ELUT) CEO reports RSU vesting and tax withholding, boosting share holdings - Stock Titan
Elutia Inc (ELUT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Elutia Inc (ELUT) Institutional Confidence - TradingKey
Elutia Inc (ELUT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Elutia Inc (ELUT) Valuation: PE, PB & Fair Value Analysis - TradingKey
ELUT: Drug-eluting biologic for breast reconstruction targets high infection rates in a $1.5B market - TradingView
Elutia Q1 2026 Earnings: EPS Misses Estimates Amid Operational ChallengesBanking Earnings Report - newsline.com
ELUT Q1 2026 Earnings: EPS Misses Estimates Despite Positive Stock ReactionCost Structure Review - dars.gov.et
Elutia Inc. (NASDAQ: ELUT) Files 8-K with Updated Company Information and Key SEC Details – June 2026 - Minichart
Elutia shareholders approve board proposals at annual meeting - Investing.com
Elutia shareholders approve board proposals at annual meeting By Investing.com - Investing.com India
Elutia Shareholders Approve Amended Incentive Plan and Governance - TipRanks
Elutia (ELUT) investors approve equity plan amendment and annual say-on-pay - Stock Titan
Elutia Inc. (ELUT) Q1 2026 Earnings: EPS Misses Estimates as Company Navigates Early-Stage PipelineRevenue Warning Signal - newsline.com
Elutia Inc Stock (ELUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
4.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):